Induction Optimization with Stelara for Crohn s Disease

Brief description of study

The purpose of this study is to compare the effectiveness of a second weight based dose of Stelara given intravenously to the standard dose administered subcutaneously at 8 weeks. In this study, the second weight-based intravenous induction dose of Stelara is considered investigational because it is outside of the FDA-approved dosing or “off-label”.

Clinical Study Identifier: s19-01401 Identifier: NCT04629196

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.